AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced that its polymer product lines are compliant with measures applying to the processing of certain animal waste to protect against transmissible spongiform encephalopathies as set forth in European Council Decision 1999/534/EC.
Khristine Carroll, AdvanSource’s Senior Vice President of Commercial Operations, stated, “AdvanSource is committed to upholding the highest risk assessment of its polymer products through rigorous processes and performance criteria while advocating efficient and effective control measures at every step of our manufacturing process. We recognize that the risk of infectious agent contamination, such as TSE and BSE, is mitigated through controlled sourcing and qualified evaluation of all our starting steps. Accordingly, we have undertaken a complete review of our materials, processes and raw material suppliers to proactively respond to the device industries growing concern regarding this issue. We are proud of the initiatives we take to respond to the concerns of our growing number of medical device customers in a proactive and timely manner and the partnerships these customers have offered us.”